Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as a sterile solution for subcutaneous use. It is employed as a disease‑modifying antirheumatic drug and as chemotherapy, targeting rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and other malignancies in adult and pediatric patients when indicated.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before distribution.

Methotrexate is an antimetabolite DMARD that modulates immune and proliferative pathways.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin lesion severity by limiting keratinocyte proliferation. - Acute lymphoblastic leukemia: interferes with malignant cell replication as part of chemotherapy protocols. - Other malignancies: used in combination regimens to inhibit tumor growth.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring shortly after administration. - Fatigue: persistent tiredness that may affect daily activities. - Oral ulcers: painful sores in the mouth or on the tongue. - Elevated liver enzymes: mild, transient increases detectable in blood tests. - Cytopenias: mild reductions in white blood cells or platelets. - Alopecia: temporary thinning or loss of scalp hair.

Serious or Rare Side Effects: - Severe hepatotoxicity: significant liver injury requiring monitoring or discontinuation. - Pulmonary fibrosis: progressive lung scarring presenting with cough and dyspnea. - Life‑threatening bone marrow suppression: profound pancytopenia leading to infection or bleeding. - Renal failure: impaired kidney function affecting drug clearance. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Teratogenicity: birth defects when exposure occurs during pregnancy.

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Liver monitoring: perform baseline and periodic liver function tests. - Hematologic monitoring: check complete blood counts regularly to detect cytopenias. - Renal function: assess creatinine clearance and adjust dose if needed. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Alcohol restriction: limit intake to reduce hepatic risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels and toxicity. - Penicillins and other β‑lactam antibiotics: may reduce renal clearance, raising exposure. - Proton pump inhibitors: can elevate methotrexate concentrations, especially at high doses.

Moderate Interactions (Monitor Closely): - Alcohol: synergistic hepatotoxic effect; limit consumption. - Live vaccines: risk of infection due to immunosuppression; avoid during therapy. - Folate supplements: may diminish therapeutic effect; adjust dosing under medical guidance.